カテゴリー： Transparency Market Research, アジア太平洋, 医療/バイオ

生物製剤受託製造のアジア太平洋市場2021年ｰ2031年：種類別（モノクローナル、抗体、組換え体、タンパク質、ワクチン、分子療法、その他）

【英語タイトル】Biologics Contract Manufacturing Market (Type: Monoclonal, Antibodies, Recombinant, Proteins, Vaccines, Molecular Therapy, and Others) - Asia Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Transparency Market Researchが出版した調査資料（TMR21DC056）・商品コード：TMR21DC056
・発行会社（調査会社）：Transparency Market Research
・発行日：2021年10月12日
・ページ数：139
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：アジア太平洋
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD5,795 ⇒換算￥753,350見積依頼/購入/質問フォーム
Site Licence（同一拠点内で共有可）USD8,795 ⇒換算￥1,143,350見積依頼/購入/質問フォーム
Enterprisewide（複数拠点内で共有可）USD11,795 ⇒換算￥1,533,350見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
Transparency Market Research社の本調査レポートは、生物製剤受託製造のアジア太平洋市場を調査対象とし、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別分析、国別分析、競争状況などの構成でまとめております。
❖ レポートの概要 ❖

Asia Pacific Biologics Contract Manufacturing Market – Scope of Report
The latest study collated and published by Transparency Market Research (TMR) analyzes the historical and present scenario of the biologics contract manufacturing market in Asia Pacific to gauge its growth potential. The study presents detailed information about important growth factors, restraints, and key trends that are creating the landscape for growth of the biologics contract manufacturing market in Asia Pacific in order to identify opportunities for stakeholders. The report also provides insightful information about the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period from 2021 to 2031.

The report offers intricate dynamics about different aspects of the biologics contract manufacturing market in Asia Pacific, which aids companies operating in the market in making strategic decisions. TMR’s study also elaborates on the significant changes that are anticipated to boost the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period. It also includes key indicator assessment that highlights growth prospects of the biologics contract manufacturing market in Asia Pacific and provides statistics related to the market in terms of value (US$ Mn).

This study covers detailed segmentation of the biologics contract manufacturing market in Asia Pacific, along with key information and competition outlook. The report provides company profiles of players that dominate the biologics contract manufacturing market in Asia Pacific, wherein various developments, expansions, and winning strategies adopted by these players have been presented in detail.

Key Questions Answered in TMR’s Report on Asia Pacific Biologics Contract Manufacturing Market

The report provides detailed information about the biologics contract manufacturing market in Asia Pacific based on comprehensive research on various factors that play a key role in accelerating the growth of the market. Information mentioned in the report answers path-breaking questions for companies that currently operate in the biologics contract manufacturing market in Asia Pacific and are looking for innovative methods to create a unique benchmark in the market in order to help them design successful strategies and make target-driven decisions.

Which segment of the biologics contract manufacturing market in Asia Pacific would emerge as a major revenue generator during the forecast period?
How are key market players successfully earning revenue in the biologics contract manufacturing market in Asia Pacific?
What would be the Y-o-Y growth trend of the biologics contract manufacturing market in Asia Pacific between 2021 and 2031?
What are the winning imperatives of leading players operating in the biologics contract manufacturing market in Asia Pacific?

Research Methodology – Asia Pacific Biologics Contract Manufacturing Market

The research methodology adopted by analysts for compiling the report on the biologics contract manufacturing market in Asia Pacific is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information obtained and endorsed by market-admissible sources, analysts have offered riveting observations and authentic forecasts of the biologics contract manufacturing market in Asia Pacific.

Primary research involved interviews with market stakeholders, investors, brand managers, vice presidents, and sales & marketing managers. Based on data obtained through interviews of genuine sources, analysts have emphasized the changing scenario of the biologics contract manufacturing market in Asia Pacific.

Secondary research involved study of annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the biologics contract manufacturing market in Asia Pacific.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global & Asia Pacific Biologics Contract Manufacturing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Biologics Contract Manufacturing: Overview
5.2. Trends in Biopharma Contract Manufacturing
5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.4. COVID-19 Pandemic Impact on Industry
6. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Proteins
6.3.3. Vaccines
6.3.4. Molecular Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Country/Sub-Region
7.1. Key Findings
7.2. Market Value Forecast, by Country/Sub-Region
7.2.1. Japan
7.2.2. South Korea
7.2.3. Taiwan
7.2.4. Singapore
7.2.5. Thailand
7.2.6. India
7.2.7. Rest of Asia Pacific
7.3. Market Attractiveness Analysis, by Country/Sub-Region
8. Japan Biologics Contract Manufacturing Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Type, 2017–2031
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.2.3. Vaccines
8.2.4. Molecular Therapy
8.2.5. Others
8.3. Market Attractiveness Analysis
8.3.1. By Type
9. South Korea Biologics Contract Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017–2031
9.2.1. Monoclonal Antibodies
9.2.2. Recombinant Proteins
9.2.3. Vaccines
9.2.4. Molecular Therapy
9.2.5. Others
9.3. Market Attractiveness Analysis
9.3.1. By Type
10. Taiwan Biologics Contract Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.2.3. Vaccines
10.2.4. Molecular Therapy
10.2.5. Others
10.3. Market Attractiveness Analysis
10.3.1. By Type
11. Singapore Biologics Contract Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Recombinant Proteins
11.2.3. Vaccines
11.2.4. Molecular Therapy
11.2.5. Others
11.3. Market Attractiveness Analysis
11.3.1. By Type
12. Thailand Biologics Contract Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Recombinant Proteins
12.2.3. Vaccines
12.2.4. Molecular Therapy
12.2.5. Others
12.3. Market Attractiveness Analysis
12.3.1. By Type
13. India Biologics Contract Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Recombinant Proteins
13.2.3. Vaccines
13.2.4. Molecular Therapy
13.2.5. Others
13.3. Market Attractiveness Analysis
13.3.1. By Type
14. Rest of Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Recombinant Proteins
14.2.3. Vaccines
14.2.4. Molecular Therapy
14.2.5. Others
14.3. Market Attractiveness Analysis
14.3.1. By Type
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Lonza Group
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.3.2. Samsung Biologics Co., Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Strategic Overview
15.3.2.4. SWOT Analysis
15.3.3. Patheon by Thermo Fisher Scientific, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Strategic Overview
15.3.3.4. SWOT Analysis
15.3.4. Siegfried Holding AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Strategic Overview
15.3.4.4. SWOT Analysis
15.3.5. Cambrex Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Strategic Overview
15.3.5.4. SWOT Analysis
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Strategic Overview
15.3.6.4. SWOT Analysis
15.3.7. Recipharm Pharmaceuticals
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Strategic Overview
15.3.7.4. SWOT Analysis
15.3.8. Catalent Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Strategic Overview
15.3.8.4. SWOT Analysis
15.3.9. WuXi Biologics
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Strategic Overview
15.3.9.4. SWOT Analysis
15.3.10. Fujifilm Holding Corporation
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Strategic Overview
15.3.10.4. SWOT Analysis
15.3.11. AbbVie, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Strategic Overview
15.3.11.4. SWOT Analysis

List of Tables

Table 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 02: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 03: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 04: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 05: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 06: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 07: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 08: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 09: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

List of Figures

Figure 01: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Type, 2020

Figure 03: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Country/Sub-Regions, 2020

Figure 04: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Type, 2020 and 2031

Figure 05: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 06: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Monoclonal Antibodies, 2017‒2031

Figure 07: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Recombinant Proteins, 2017‒2031

Figure 08: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Vaccines, 2017‒2031

Figure 09: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Molecular Therapy, 2017‒2031

Figure 10: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Others, 2017–2031

Figure 11: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Region, 2021–2031

Figure 12: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Region, 2020 and 2031

Figure 13: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 14: Japan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 15: Japan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 16: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 17: South Korea Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 18: South Korea Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 19: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 20: Taiwan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 21: Taiwan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 22: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 23: Singapore Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 24: Singapore Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 25: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 26: Thailand Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 27: Thailand Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 28: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 29: India Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 30: India Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 31: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 32: Rest of Asia Pacific Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 33: Rest of Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

★調査レポート[生物製剤受託製造のアジア太平洋市場2021年ｰ2031年：種類別（モノクローナル、抗体、組換え体、タンパク質、ワクチン、分子療法、その他）] (コード：TMR21DC056)販売に関する免責事項を必ずご確認ください。
★調査レポート[生物製剤受託製造のアジア太平洋市場2021年ｰ2031年：種類別（モノクローナル、抗体、組換え体、タンパク質、ワクチン、分子療法、その他）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の生物製剤受託製造市場2021年ｰ2031年：種類別（モノクローナル抗体、組換えタンパク質、ワクチン、分子療法、その他[RNAi、アンチセンスRNA、その他]）
    TMR22FB032 / Transparency Market Research / 2021年11月 / Transparency Market Research社の本調査レポートは、世界の生物製剤受託製造市場を調査対象とし、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、新型コロナウイルス感染症の影響分析、種類別（モノクローナル抗体、組換えタンパク質、ワクチン、分子療法、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でまとめています。 ・序論 ・仮定・調査手法...
  • 世界の生物製剤契約生産市場2021-2031：種類別（モノクローナル抗体、組換えタンパク質、ワクチン、分子療法、その他[RNAi、アンチセンスRNA、その他]）
    TMR22JA033 / Transparency Market Research / 2021年11月10日 / Transparency Market Research社の本調査レポートは、世界の生物製剤契約生産市場を調査・分析し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（モノクローナル抗体、組換えタンパク質、ワクチン、分子療法、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。 ・序論 ・仮定/調査手法...
  • 世界のアルブミン市場2021年-2028年：種類別（ヒト血清、ウシ血清、組換え体）、用途別（治療、製剤、その他）、地域別
    RDV22AU024 / Research Dive / 2022年4月 / Research Dive社の当調査資料では、世界のアルブミン市場について多面的に分析し、調査手法、エグゼクティブサマリー、市場概要、種類別（ヒト血清、ウシ血清、組換え体）分析、用途別（治療、製剤、その他）分析、地域別分析、企業情報などの内容をまとめております。なお、当書に掲載されている企業情報には、Baxter International Inc.、China Biologic...
  • 世界のペプチド合成市場（～2026年）：試薬別（樹脂、アミノ酸、染料）、機器別（ペプチド合成装置、クロマトグラフィー、凍結乾燥機）、技術別（固相、液相、ハイブリッド・組換え体）、エンドユーザー別（製薬、バイオテクノロジー、CRO）
    BT6462 / MarketsandMarkets / 2022年1月6日 / マーケッツアンドマーケッツ社は世界のペプチド合成市場規模が2021年515百万ドルから2026年730百万ドルまで、年平均7.2％成長すると予測しています。本調査レポートでは、ペプチド合成の世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別（試薬、機器、サービス）分析、技術別（固相ペプチド合成（SPPS）、液相ペプチド合成、ハイブリッド・組換え体）分析、エンドユーザー別（製薬・バイオテクノロジー企業、CDMO・CRO、学術・研究機関）分析、地域別分析、競争状況、企業情報などを掲載しております。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト...
  • インドの動物医療市場2022ｰ2031：動物種類別（ウシ、ブタ、ヒツジ、家禽）、治療種類別（治療薬、ワクチン）
    TMR22JL106 / Transparency Market Research / 2022年5月 / Transparency Market Research社の本調査レポートでは、インドの動物医療市場市場について総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、動物種類別分析、治療種類別分析、流通チャネル別分析、競争状況などの内容をまとめております。なお、本書に掲載されている企業情報にはIDEXX Laboratories, Inc.、Virbac...

    • ◆H&Iグローバルリサーチのお客様（例）◆